Traphagen Investment Advisors LLC Has $638,000 Position in Pfizer Inc. $PFE

Traphagen Investment Advisors LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 26,303 shares of the biopharmaceutical company’s stock after selling 1,284 shares during the period. Traphagen Investment Advisors LLC’s holdings in Pfizer were worth $638,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Matisse Capital acquired a new position in shares of Pfizer during the 2nd quarter valued at $282,000. Citizens National Bank Trust Department lifted its position in shares of Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 395 shares during the period. Abel Hall LLC increased its stake in Pfizer by 125.1% during the 2nd quarter. Abel Hall LLC now owns 25,900 shares of the biopharmaceutical company’s stock valued at $628,000 after purchasing an additional 14,395 shares in the last quarter. Spectrum Asset Management Inc. NB CA increased its stake in Pfizer by 3.6% during the 2nd quarter. Spectrum Asset Management Inc. NB CA now owns 17,679 shares of the biopharmaceutical company’s stock valued at $429,000 after purchasing an additional 619 shares in the last quarter. Finally, Proffitt & Goodson Inc. increased its stake in Pfizer by 23.0% during the 2nd quarter. Proffitt & Goodson Inc. now owns 4,257 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 795 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $26.27 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market cap of $149.36 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 0.86 and a beta of 0.55. The company has a fifty day moving average price of $24.76 and a 200-day moving average price of $24.14.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the business posted $0.60 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Bank of America boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.